相关实验视频
Updated: Jun 30, 2025

09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
9.4K
用基斯普拉丁基化疗治疗头癌患者的听力学评估:一项纵向研究
Nurudeen Adebola Shofoluwe1, Iliyasu Yunusa Shuaibu1, Ibrahim Babatunde Mohammed1
1Department of Surgery, Division of Otorhinolaryngology, Faculty of Clinical Sciences, College of Medical Sciences, Ahmadu Bello University/Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
概括
基于西斯的化疗对头癌患者的听力有显著影响,导致短期听力损伤. 许多患者在治疗开始之前就会经历听力损失.
科学领域:
- 在瘤学瘤学.
- 耳部毒理学 耳部毒理学
- 听力学 听力学是指听力学.
背景情况:
- 全球头癌发病率的增加.
- 广泛使用基于的化学放射疗法治疗头部和部恶性瘤.
- 需要了解治疗对患者健康的副作用.
研究的目的:
- 为了确定基于西斯的化疗对头癌患者听力的影响.
- 评估化疗前后的听力值和听力损失程度.
- 为了评估这种患者群体中耳毒性的发生率.
主要方法:
- 基于医院的纵向病例控制研究.
- 54名参与者接受了针对头部和部癌症的基于的化疗.
- 每隔3个月和6个月进行听力评估;使用SPSS v20进行数据分析.
主要成果:
- 在化疗前,40.7%的患者有听力损失.
- 经过6个月的西斯普拉丁治疗,62.9%的耳朵显示出听力值的变化.
- 在治疗6个月后,耳毒性的总发病率为62.9%.
结论:
- 在化疗前,头癌患者存在显著的听力损伤.
- 基于西斯普拉丁的化疗与显著的短期听力损伤有关.
- 耳毒性是一种相当大的副作用,需要在头癌患者中进行监测.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200

